Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Fulgent Genetics, Inc.
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.
IPO Date: September 29, 2016
Sector: Healthcare
Industry: Medical Diagnostics and Research
Market Cap: $550.12M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.92 | 2.94%
Avg Daily Range (30 D): $0.24 | 1.23%
Avg Daily Range (90 D): $0.34 | 1.78%
Institutional Daily Volume
Avg Daily Volume: .3M
Avg Daily Volume (30 D): .17M
Avg Daily Volume (90 D): .27M
Trade Size
Avg Trade Size (Sh.): 63
Avg Trade Size (Sh.) (30 D): 43
Avg Trade Size (Sh.) (90 D): 46
Institutional Trades
Total Inst.Trades: 1,715
Avg Inst. Trade: $1.85M
Avg Inst. Trade (30 D): $.88M
Avg Inst. Trade (90 D): $1.48M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.98M
Avg Closing Trade (30 D): $.88M
Avg Closing Trade (90 D): $1.57M
Avg Closing Volume: 44.65K
   
News
Jul 15, 2025 @ 11:41 PM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
Jul 1, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
Jun 23, 2025 @ 4:53 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
Jun 10, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating Semle...
Source: N/A
Jun 3, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating EchoS...
Source: Bragar Eagel & Squire, P.C.
Financials
  TTM Q1 2025 Q4 2024
Basic EPS
Diluted EPS
Revenue $ 292.45M $ 73.46M $ 76.21M
Gross Profit $ 113.46M $ 28.35M $ 31.85M
Net Income / Loss $ -41.87M $ -11.9M $ -6.19M
Operating Income / Loss $ -71.92M $ -19.8M $ -16.14M
Cost of Revenue $ 178.99M $ 45.12M $ 44.37M
Net Cash Flow $ 12.74M $ 12.14M $ -2.9M
PE Ratio